advances in nuclear cardiology matthew schumaecker, md, facc, fasnc medical director, nuclear...

36
Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor of Medicine Virginia Tech Carilion School of Medicine

Upload: agnes-reeves

Post on 14-Jan-2016

221 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Advances in Nuclear Cardiology

Matthew Schumaecker, MD, FACC, FASNC

Medical Director, Nuclear Cardiology

Carilion Clinic Cardiology

Assistant Professor of MedicineVirginia Tech Carilion School of Medicine

Page 2: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Educational Objectives

• Review advances in nuclear cardiology in:• Novel radiopharmaceuticals• Advances in camera software and hardware• Molecular imaging

Page 3: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Very Brief History of Nuclear Cardiology

• 1958 Scintillation Camera: Hal Anger

• 1972 Thallium 201

• 1976 SPECT camera: Keys, Jaszczak

• 1984 Cardiac PET Rb-82

• 1996 Cardiolite® (sestamibi) approved

Page 4: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Current State

• Most nuclear cameras in use are the same technology from 1970’s

• Sestamibi has been on the market for over 17 years

• Thallium mostly gone • MRI has replaced MUGA as gold standard

for LVEF assessment• PET imaging only in large academic centers

Page 5: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

PET

• Advantages of PET over SPECT• Higher energy resolution • Mandatory attenuation correction• Quantification of coronary blood flow

• Disadvantages of PET over SPECT• Camera is MUCH more expensive• Radioisotopes are very short-lived

Page 6: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

SPECT vs PET

Tc99m

140 keVɣray

F18

E=mc2

511keVphoton

511keVphoton

e-

β+

Page 7: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

18F-Flurpiridaz PET

• Half life of currently utilized cardiac PET perfusion agents:

Agent T1/2

N-13 132 seconds

O-15 148 seconds

Rb-82 75 seconds

Page 8: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

18F-Flurpiridaz PET

• 18F Fludeoxyglucose has t1/2 of 110 minutes

BUT

• This is a viability agent, not a perfusion agent

Page 9: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

18F-Flurpiridaz PET

Jamshid Maddahi, M.D., FACC, FASNC, and René R. S. Packard, M.D.

Page 10: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-BMIPP

• 99mTc can be used to evalulate chest pain at rest but only if patient is having pain at the time.

Page 11: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Cardiac Memory

• Myocytes preferentially metabolize FFA

• In ischemia millieu, switch to glycolysis

Page 12: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Cardiac Memory

• Substrate switch can last up to 24 hours

• If injected with 123I-BMIPP, SPECT images will show defect if patient has been ischemic within 24 hours

Dilsizian et al, Circ 2005;112:2169-2174

Page 13: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

BMIPP Trial

J Am Coll Cardiol. 2010 Jul 20;56(4):290-9

Page 14: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-MIBG

• MIBG is a sympathetic neurotransmitter radionuclide analog

• Cardiac uptake of MIBG is assessed by heart/mediastinal ratio.

• Correlates to heart failure severity, pre-disposition to cardiac arrhythmias, and poor prognosis

Page 15: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-MIBG

• As CHF progresses, there is a reduction in the number of presynaptic neurons and the function of the norepinephrine terminal resulting in decreased uptake of mIBG.

• Therefore, lower H/M ratios confer a more negative prognosis

Page 16: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-MIBG

Yazaki et al. Cardiomyopathies Chap 11

Page 17: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-MIBG ADMIRE-HF Trial

Jacobson et al J Am Coll Cardiol. 2010;55(20):2212-2221

 ”Two-year event rate was 15% for H/M ≥1.60 and 37% for H/M <1.60”

Page 18: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-MIBG ADMIRE-HF Trial

Jacobson et al J Am Coll Cardiol. 2010;55(20):2212-2221

Page 19: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

123I-MIBG

> $1000 per dose No reimbursement in US

Page 20: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

SPECT/CT

Gaemperli et al, Journal Nuc Med May 2007; 5:696

Page 21: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

FBP vs OSEM

• Filtered backprojection suppresses high-frequency image data thereby decreasing noise. This causes image blurring and subjects the image to ramp filter artifact

• Iterative reconstruction provides an estimated reconstruction volume and compares it to image. This occurs until images converge

Page 22: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Depth DependentResolution Loss

Page 23: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Depth DependentResolution Recovery

• Wide beam reconstruction suppresses noise and enhances signal-to-noise ratio by modeling the statistical characteristics the collimator detector response.

• Statistical filters using Gaussian and Poisson Fourier transforms allow the deeper voxels to appear as they were closer, thereby eliminating DDRL

Page 24: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Depth DependentResolution Recovery

Page 25: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Depth DependentResolution Recovery

Page 26: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Hardware: Optimized Detector Geometry

Page 27: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Hardware: Optimized Detector Geometry

Page 28: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Solid State Detectors

Page 29: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Attenutation Correction

Two ways to do AC:

Page 30: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Attenutation Correction

Page 31: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Prone Imaging

• Shifts the heart off the diaphragm and places breasts in different position.

• Not as valuable as attenuation correction

• BUT – added counts in prone imaging are always real

Page 32: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Molecular Imaging

• Two major targets:• Vulnerable Plaque• Cardiac remodeling

Page 33: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Potential Targets

• IL-6

• VCAM – 1

• LT B4

• Matrix metalloproteases

• Cathepsins

• Anti-myosin antibodies

• Beta receptors

• ACE receptors

Page 34: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Apoptosis

Nahrendorf M et al. Circ Cardiovasc Imaging 2009;2:56-70

Copyright © American Heart Association

Page 35: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor

Atherosclerosis imaging

Nahrendorf M et al. Circ Cardiovasc Imaging 2009;2:56-70

Copyright © American Heart Association

Page 36: Advances in Nuclear Cardiology Matthew Schumaecker, MD, FACC, FASNC Medical Director, Nuclear Cardiology Carilion Clinic Cardiology Assistant Professor